Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries

Published:2021-02-24 Issue:2 Volume:4 Page:e210030
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Green Angela K.¹²,Curry Michael²,Trivedi Niti²,Bach Peter B.²,Mailankody Sham²³

Affiliation:

1. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York

3. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2776748/green_2021_oi_210003_1613516808.17409.pdf

Reference41 articles.

1. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.;Elting;Cancer,2006

2. The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials.;Clarey;Ann Oncol,2012

3. Participation in cancer clinical trials: race-, sex-, and age-based disparities.;Murthy;JAMA,2004

4. Representation of minorities and women in oncology clinical trials: review of the past 14 Years.;Duma;J Oncol Pract,2018

5. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.;Ford;Cancer,2008

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands;Journal of Cancer Policy;2024-09

2. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry;PLOS ONE;2024-08-27

3. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC;Advances in Therapy;2024-06-25

4. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer;Gynecologic Oncology;2024-05

5. Ownership and Interoperability Challenges of Alzheimer Monoclonal Antibody Registries;JAMA Neurology;2023-12-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3